News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Israeli forces pressed into central Gaza after a strike killed two brothers, increasing regional conflict and market risk.
  • QatarEnergy said undamaged Ras Laffan LNG units could return to full output in about a month, easing near-term gas supply concerns.
  • FCC approved imports of select Chinese-made toy drones after Pentagon review, reopening some U.S. consumer drone supply.
  • Thyssenkrupp approved spinning off its materials unit as 'tk accelis' with a planned Frankfurt listing and pro rata minority share allocation.
  • Olin and Huntsman announced a definitive all-stock merger, and Olin shares fell amid dilution and debt concerns.
  • IMF cut Bosnia's 2026 growth forecast to 2%, flagging Middle East conflict-driven energy costs and weaker EU demand.
  • Gold and miners rallied as markets trimmed 2026 Fed hike odds, signaling a shift toward safe-haven assets.

Latest Articles

TD Cowen Keeps Hold on Beta Bionics at $17 After FDA Warning Letter; Financials and Q4 Revenue Provide Cushion

TD Cowen Keeps Hold on Beta Bionics at $17 After FDA Warning Letter; Financials and Q4 Revenue Provide Cushion

TD Cowen has reiterated a Hold rating and a $17.00 price target on Beta Bionics (BBNX) after the company received an FDA Warning Letter. The firm’s initial read suggests the letter does not impose burdensome remediation demands and will not block product sales or 510(k) submissions. Beta Bionics reported preliminary fourth-quarter 2025 revenue of a…

BMO Keeps Neutral Rating on Air Products After Another Strong Quarter

BMO Keeps Neutral Rating on Air Products After Another Strong Quarter

BMO Capital reaffirmed its Market Perform rating on Air Products & Chemicals Inc. (NYSE:APD) and held a $282.00 price target after the company reported a solid quarter that outpaced analyst forecasts. The research note highlighted management's pricing and efficiency controls, clarified balance-sheet exposure for the NEOM project, and assigned CBAM …

BMO Reaffirms Outperform on Canadian National, Sets $158 Price Target as Company Reports Strong Q4 Results

BMO Reaffirms Outperform on Canadian National, Sets $158 Price Target as Company Reports Strong Q4 Results

BMO Capital has reiterated an Outperform rating on Canadian National Railway (CNI) with a $158.00 price target, reflecting confidence in the company’s margin profile and cash generation even as management warns of essentially flat freight volumes in 2026. Fourth-quarter adjusted results topped expectations on productivity gains, but analysts have t…

Capgemini to Divest U.S. Government Unit Amid Scrutiny Over ICE Contract

Capgemini to Divest U.S. Government Unit Amid Scrutiny Over ICE Contract

Capgemini announced it will sell its U.S. subsidiary, Capgemini Government Solutions (CGS), and begin a divestment process immediately after facing questions from French lawmakers over a contract CGS signed with U.S. Immigration and Customs Enforcement (ICE). The group said U.S. legal constraints restricted its ability to govern certain CGS activit…

ASML: Buy the Advanced Node Monopoly with a Measured Long Trade

ASML: Buy the Advanced Node Monopoly with a Measured Long Trade

ASML's monopoly on EUV lithography is powering another leg of compounding: record Q4 orders (€13.2bn), 2026 guidance raised to €34-39bn and a €12bn buyback underpin growth and capital returns. Technicals show bullish momentum, but a steep valuation (PE ~51, PB ~24.7) and China exposure create near-term jolt risk. Trade plan: go long at $1426.74, ta…